The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” strengthens Alpha Cognition’s existing portfolio supporting both ALPHA-1062 and ZUNVEYL
The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
Opioid dependence remains a major driver of death and disease worldwide
The new capital is expected to fund the company through 2029
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The trial also demonstrated significant improvements across multiple secondary endpoints
Subscribe To Our Newsletter & Stay Updated
